









Markets
/
Stocks
/
nasdaq-bntx
/

Biontech SE

BNTX

88.770USD

+1.960+2.26%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

22.31BMarket Cap

LossP/E TTM



Biontech SE

88.770

+1.960+2.26%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biontech SE

Currency: USD Updated: 2026-03-24

Key Insights

Biontech SE's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 30 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 130.06.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biontech SE's Score

Industry at a Glance

Industry Ranking

30 / 391

Overall Ranking

120 / 4547

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Biontech SE Highlights

StrengthsRisks

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Fairly Valued

The company’s latest PE is -21.69, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 54.72M shares, decreasing 0.02% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 188.70K shares of this stock.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

130.062

Target Price

+45.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-24

The current financial score of Biontech SE is 8.83, ranking 22 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 781.57M, representing a year-over-year decrease of 28.86%, while its net profit experienced a year-over-year decrease of 209.66%.

Score

Industry at a Glance

Previous score

8.83

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.32

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.81

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Biontech SE's Company Valuation

Currency: USD Updated: 2026-03-24

The current valuation score of Biontech SE is 8.27, ranking 53 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -21.69, which is -1152.14% below the recent high of 228.22 and -338.92% above the recent low of -95.21.

Score

Industry at a Glance

Previous score

8.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 30/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-24

The current earnings forecast score of Biontech SE is 7.90, ranking 262 out of 391 in the Biotechnology & Medical Research industry. The average price target is 140.00, with a high of 181.00 and a low of 82.11.

Score

Industry at a Glance

Previous score

8.09

Change

-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

130.062

Target Price

+47.11%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Biontech SE

BNTX

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-24

The current price momentum score of Biontech SE is 7.01, ranking 96 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 106.30 and the support level at 73.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.11

Change

-0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.853

Sell

RSI(14)

37.968

Neutral

STOCH(KDJ)(9,3,3)

24.959

Neutral

ATR(14)

4.817

High Vlolatility

CCI(14)

-48.578

Neutral

Williams %R

60.360

Sell

TRIX(12,20)

-0.821

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

88.514

Buy

MA10

89.926

Sell

MA20

95.533

Sell

MA50

104.572

Sell

MA100

101.674

Sell

MA200

103.996

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-24

The current institutional shareholding score of Biontech SE is 3.00, ranking 195 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 25.43%, representing a quarter-over-quarter decrease of 1.01%. The largest institutional shareholder is PRIMECAP Management, holding a total of 3.80M shares, representing 1.44% of shares outstanding, with 14.29% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

AT Impf GmbH

101.85M

-0.62%

Medine GmbH

40.13M

-0.75%

Fidelity Management & Research Company LLC

4.98M

-28.65%

T. Rowe Price Investment Management, Inc.

4.83M

+34.32%

Flossbach von Storch AG

4.23M

-0.00%

PRIMECAP Management Company

Star Investors

3.87M

-3.27%

Dodge & Cox

Star Investors

3.65M

+315.65%

BNP Paribas Securities Corp. North America

1.10M

-13.50%

Temasek Holdings Pte. Ltd.

1.51M

Risk Assessment

Currency: USD Updated: 2026-03-24

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Biontech SE is 7.65, ranking 9 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 1.59. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.